Dr Xiaomin Zhong
Contact information
Research groups
Xiaomin Zhong
BSc, MSc, PhD
Health Data Epidemiologist
Xiaomin (Billy) Zhong’s work focuses on leveraging large-scale health data to inform public health policy and clinical care, with a particular emphasis on cancer.
Billy has conducted published studies exploring complex disease associations and developing clinical risk prediction models. He has used population-level datasets, including primary and secondary care records, to investigate the impacts of events such as the COVID-19 pandemic on disease burden and outcomes. His research spans areas such as cardiovascular disease, infectious disease, and cancer.
Billy has contributed to healthcare-driven projects using linked data to create risk prediction models. These models generate personalised risk scores based on factors like age, sex, clinical and medication history, ethnicity, and socioeconomic status. These refined models have been integrated into a Knowledge Support System (KSS) to aid clinical decision-making.
His work involves collaborations with research groups, including Oxford University Hospitals (OUH), the University of Manchester, and the UK Health Security Agency (UKHSA). He uses linked datasets from sources such as the Clinical Practice Research Datalink (CPRD), OpenSAFELY, and the British Heart Foundation Data Science Centre, (BHF DSC) as well as clinical trials like ASCEND PLUS.
Billy holds a PhD in Health Informatics and an MSc in Health Data Science from the University of Manchester, and a BSc from Peking University, China. He teaches on the Health Data Science MSc at Manchester and supervises MSc Global Health Science and Epidemiology projects at Oxford.
Recent publications
-
Antibiotics for common infections in primary care before, during and after the COVID-19 pandemic: cohort study of extent of prescribing based on risks of infection-related hospital admissions
Journal article
Fahmi A. et al, (2025), Journal of the Royal Society of Medicine
-
Correction: Evaluation of the impact of COVID-19 pandemic on hospital admission related to common infections: Risk prediction models to tackle antimicrobial resistance in primary care.
Journal article
Fahmi A. et al, (2025), PLoS One, 20
-
Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
Conference paper
Sun Y. et al, (2025), JOURNAL OF CLINICAL ONCOLOGY, 43, 155 - 155
-
Rapid systematic review on risks and outcomes of sepsis: the influence of risk factors associated with health inequalities
Journal article
Bladon S. et al, (2024), International Journal for Equity in Health, 23
-
Trends in incidence of pneumothorax in England before, during and after the COVID-19 pandemic (2017-2023): a population-based observational study.
Journal article
Zhong X. et al, (2024), Lancet Reg Health Eur, 44